Mimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera. research Mental Health cardiology Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Biotech FDA approves Protagonist and Takeda’s drug for rare blood cancer Mimrylo, a weekly injection, is a new kind of treatment…
The Food and Drug Administration on Friday approved a new treatment for a rare and slow-growing cancer that causes an overproduction of red blood cells.
The drug, called rusfertide, was developed by the biotech company Protagonist Therapeutics. It will be sold by Takeda, the Japanese pharma company, under the brand name Mimrylo.
Administered via a weekly injection, Mimrylo was cleared to treat polycythemia vera, a chronic blood cancer in which overproduction of red blood cells thickens a patient’s blood, resulting in higher risk for life-threatening heart attacks, strokes, and blood clots.
Continue to STAT+ to read the full story…
US Pharma Marketing